1st Quarter - Report

RED+BLUE STRATEGIES for PEW CHARITABLE TRUSTS

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 1625/PL 115-141 - Consolidated Appropriations Act of 2018 - Issues related to policies regarding antibiotic resistance, compounding, policies surrounding access to prescription medications and policies to combat the opioid crisis in the United States. H.R. 1301/PL 115-124 - Continuing Resolution of 2018 - Issues related access and affordability of prescription medications in the United States, treatment of biosimilars and generics in public and private insurance and policies to combat the opioid crisis in the United States. CMS regulations related to Medicare Part D and promulgation of laws related to curbing substance use disorder among Medicare beneficiaries. S. 1334/H.R. 2797 - Patient Choice and Quality Care Act of 2017 - Issues related to better integration of end-of-life and palliative care into the nation's health care system. H.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. Issues related to antibiotic innovation and advancement Issues related to monograph reform. Issues related to health information technology, unique device identifiers on Medicare claims forms, and other critical policies to promote device safety. Issues related to over the counter medications and supplements.

LobbyistCovered position, as disclosed
MEGAN HAUCK MARSHALL —
MELANIE JAN NATHANSON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2797 (115th), H.R. 1301 (115th), H.R. 1625 (115th), S. 1334 (115th), H.R. 2871 (115th)

Medicare/Medicaid MMM

H.R. 1625/PL 115-141 - Consolidated Appropriations Act of 2018 - Issues related to policies regarding antibiotic resistance, compounding, policies surrounding access to prescription medications and policies to combat the opioid crisis in the United States. H.R. 1301/PL 115-124 - Continuing Resolution of 2018 - Issues related access and affordability of prescription medications in the United States, treatment of biosimilars and generics in public and private insurance and policies to combat the opioid crisis in the United States. CMS regulations related to Medicare Part D and promulgation of laws related to curbing substance use disorder among Medicare beneficiaries. Issues related to health information technology, unique device identifiers on Medicare claims forms, and other critical policies to promote device safety.

LobbyistCovered position, as disclosed
MEGAN HAUCK MARSHALL —
MELANIE JAN NATHANSON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1301 (115th), H.R. 1625 (115th)

Pharmacy PHA

H.R. 1625/PL 115-141 - Consolidated Appropriations Act of 2018 - Issues related to policies regarding antibiotic resistance, compounding, policies surrounding access to prescription medications and policies to combat the opioid crisis in the United States. H.R. 1301/PL 115-124 - Continuing Resolution of 2018 - Issues related access and affordability of prescription medications in the United States, treatment of biosimilars and generics in public and private insurance and policies to combat the opioid crisis in the United States. CMS regulations related to Medicare Part D and promulgation of laws related to curbing substance use disorder among Medicare beneficiaries. S. 1334/H.R. 2797 - Patient Choice and Quality Care Act of 2017 - Issues related to better integration of end-of-life and palliative care into the nation's health care system. H.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. Issues related to antibiotic innovation and advancement Issues related to monograph reform. Issues related to health information technology, unique device identifiers on Medicare claims forms, and other critical policies to promote device safety. Issues related to over the counter medications and supplements.

LobbyistCovered position, as disclosed
MEGAN HAUCK MARSHALL —
MELANIE JAN NATHANSON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1625 (115th), H.R. 2797 (115th), H.R. 2871 (115th), S. 1334 (115th), H.R. 1301 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.